JNJ - Johnson & Johnson
NEXT EARNINGS:
Apr 14, 2026
EPS Est: $2.70
|
Rev Est: $23.6B
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$229.33
DETAILS
HIGH:
$265.00
LOW:
$190.00
MEDIAN:
$220.00
CONSENSUS:
$229.33
DOWNSIDE:
6.88%
Market Cap:
593.51B
Volume:
7,236,282
Avg Volume:
8,971,428
52 Week Range:
141.5-247.25
Sector:
Healthcare
Industry:
Drug Manufacturers - General
Beta:
0.35
Last Dividend:
$5.20
Exchange:
NYSE
Country:
US
Employees:
138,100
IPO Date:
1943-01-02
EPS (TTM):
11.03
P/E Ratio:
18.75
Revenue (TTM):
94.19B
Total Assets:
199.21B
Total Debt:
47.93B
Cash & Equiv:
19.71B
Rev Growth (5Y):
2.3%
EPS Growth (5Y):
11.5%
FCF Growth (5Y):
-0.2%
ROCE:
22.5%
Debt/Equity:
0.59
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-01-21 | $2.46 | $2.46 | 0.0% | $24.6B | $24.1B | +1.7% |
| 2025-10-14 | $2.80 | $2.76 | +1.4% | $24.0B | $23.8B | +1.0% |
| 2025-07-16 | $2.77 | $2.68 | +3.4% | $23.7B | $22.9B | +3.9% |
| 2025-04-15 | $2.77 | $2.58 | +7.4% | $21.9B | $21.6B | +1.6% |
| 2025-01-22 | $2.04 | $1.99 | +2.5% | $22.5B | $22.4B | +0.4% |
| 2024-10-15 | $2.42 | $2.21 | +9.5% | $22.5B | $22.2B | +1.3% |
| 2024-07-17 | $2.82 | $2.71 | +4.1% | $22.4B | $22.3B | +0.5% |
| 2024-04-16 | $2.71 | $2.64 | +2.7% | $21.4B | $21.4B | 0.0% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 94.19B | 88.82B | 85.16B | 79.99B | 78.74B | 82.58B | 82.06B | 81.58B | 76.45B | 71.89B | 70.07B | 74.33B |
| Net Income | 26.80B | 14.07B | 35.15B | 17.94B | 20.88B | 14.71B | 15.12B | 15.30B | 1.30B | 16.54B | 15.41B | 16.32B |
| EPS | 11.03 | 5.84 | 13.88 | 6.83 | 7.93 | 5.59 | 5.74 | 5.75 | 0.48 | 6.08 | 5.57 | 5.86 |
| Total Assets | 199.21B | 180.10B | 167.56B | 187.38B | 182.02B | 174.89B | 157.73B | 152.95B | 157.30B | 141.21B | 133.41B | 130.36B |
| Total Debt | 47.93B | 36.63B | 29.33B | 39.64B | 33.75B | 35.27B | 27.70B | 30.48B | 34.58B | 27.13B | 19.86B | 18.76B |
| Cash & Equivalents | 19.71B | 24.11B | 21.86B | 12.89B | 14.49B | 13.98B | 17.30B | 18.11B | 17.82B | 18.97B | 13.73B | 14.52B |
| Operating Cash Flow | 24.53B | 24.27B | 22.79B | 21.19B | 23.41B | 23.54B | 23.42B | 22.20B | 21.06B | 18.77B | 19.28B | 18.47B |
| Free Cash Flow | 19.70B | 19.84B | 18.25B | 17.18B | 19.76B | 20.19B | 19.92B | 18.53B | 17.78B | 15.54B | 15.82B | 14.76B |
| FCF per Share | 8.11 | 8.24 | 7.20 | 6.58 | 7.52 | 7.67 | 7.57 | 6.96 | 6.63 | 5.74 | 5.74 | 5.30 |
| Book Value | 81.54B | 71.49B | 68.77B | 76.80B | 74.02B | 63.28B | 59.47B | 59.75B | 60.16B | 70.42B | 71.15B | 69.75B |
| Cash & ST Investments | 20.10B | 24.52B | 22.93B | 22.28B | 31.61B | 25.18B | 19.29B | 19.69B | 18.30B | 41.91B | 38.38B | 33.09B |
| ROC Equity | 0.33 | 0.20 | 0.51 | 0.23 | 0.28 | 0.23 | 0.25 | 0.26 | 0.02 | 0.23 | 0.22 | 0.23 |